Uncategorized
FDA hits Newron’s phase 3 schizophrenia trial with clinical hold in US after patient death
The FDA has halted U.S. enrollment for Newron Pharmaceuticals’ phase 3 schizophrenia trial, following the death of a patient outside of the country.